NexgenRX Inc. (NXG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NexgenRX Inc. (NXG) has a cash flow conversion efficiency ratio of 0.106x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$880.82K ≈ $637.17K USD) by net assets (CA$8.29 Million ≈ $6.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NXG equity financing ratio to measure how much of total assets are equity-financed.
NexgenRX Inc. - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how NexgenRX Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NexgenRX Inc. (NXG) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
NexgenRX Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NexgenRX Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sareum Hldgs Plc
LSE:SAR
|
-0.763x |
|
Crest Builder Holdings Bhd
KLSE:8591
|
0.264x |
|
Cubic Digital Technology Co Ltd
SHE:300344
|
-0.061x |
|
Kyobo 3 SPAC
KQ:208710
|
0.033x |
|
Eureka Design Public Company Limited
BK:UREKA
|
0.002x |
|
Siab Holdings Bhd
KLSE:0241
|
-0.098x |
|
Brookside Energy Limited
F:8F3
|
0.051x |
|
Jameson Resources Ltd
AU:JAL
|
0.005x |
Annual Cash Flow Conversion Efficiency for NexgenRX Inc. (2013–2024)
The table below shows the annual cash flow conversion efficiency of NexgenRX Inc. from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see NXG company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$7.62 Million ≈ $5.52 Million |
CA$1.15 Million ≈ $832.04K |
0.151x | -8.88% |
| 2023-12-31 | CA$7.71 Million ≈ $5.58 Million |
CA$1.28 Million ≈ $924.01K |
0.166x | +37.46% |
| 2022-12-31 | CA$8.85 Million ≈ $6.40 Million |
CA$1.07 Million ≈ $771.17K |
0.120x | -69.41% |
| 2021-12-31 | CA$9.71 Million ≈ $7.03 Million |
CA$3.82 Million ≈ $2.77 Million |
0.394x | -18.05% |
| 2020-12-31 | CA$5.52 Million ≈ $3.99 Million |
CA$2.65 Million ≈ $1.92 Million |
0.480x | -15.42% |
| 2019-12-31 | CA$1.84 Million ≈ $1.33 Million |
CA$1.05 Million ≈ $756.44K |
0.568x | +319.14% |
| 2018-12-31 | CA$1.96 Million ≈ $1.42 Million |
CA$-507.38K ≈ $-367.03K |
-0.259x | -97.65% |
| 2017-12-31 | CA$1.96 Million ≈ $1.42 Million |
CA$-257.35K ≈ $-186.16K |
-0.131x | -120.25% |
| 2016-12-31 | CA$758.06K ≈ $548.37K |
CA$490.96K ≈ $355.16K |
0.648x | +55.58% |
| 2015-12-31 | CA$-83.93K ≈ $-60.71K |
CA$-34.94K ≈ $-25.27K |
0.416x | -65.35% |
| 2014-12-31 | CA$-464.55K ≈ $-336.05K |
CA$-558.18K ≈ $-403.78K |
1.202x | +105.71% |
| 2013-12-31 | CA$-36.81K ≈ $-26.63K |
CA$774.08K ≈ $559.95K |
-21.026x | -- |
About NexgenRX Inc.
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. The company offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. It also provides ancillary services. NexgenRx Inc. was incorporated in 2003 and is headquarte… Read more